Close Menu

DigiLab

The National Institutes of Health has awarded a team of Harvard University researchers nearly $300,000 to develop a new microarray platform capable of imaging millions of bacterial cells in an overnight experiment.

Under the terms of the deal, Holliston, Mass.-based Digilab will sell Axela's Ziplex system for gene and protein expression analysis and dotLab mX system for real-time immunoassays.

The deal calls for Digilab to market new versions of Axela's proprietary flow-through technologies, the Ziplex system and the dotLab mX system.

Nearly four years after it acquired Harvard Bioscience's Genomic Solutions business, DigiLab is looking to parlay those microarray assets into the market for live cell arrays, and the stem cell research market in particular.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.